On December 6, 2019 MSD K.K. (president and CEO Jannie Oosthuizen, Chiyoda-ku, Tokyo) and Taiho Pharmaceutical Co., Ltd. (president and CEO Masayuki Kobayashi, Chiyoda-ku, Tokyo) reported that they have agreed to terminate their co-promotion contract in Japan at the end of December 2019 for KEYTRUDA (pembrolizumab [genetical recombination]), anti-PD-1 therapy manufactured and marketed by MSD (Press release, Taiho, DEC 6, 2019, View Source [SID1234551968]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

KEYTRUDA was launched on February 15, 2017 and has been co-promoted by MSD and Taiho Pharmaceutical in Japan. From January 2020, MSD will continue manufacturing, distribution and promotion of KEYTRUDA.

MSD and Taiho Pharmaceutical believe that they could make a significant contribution to patients and healthcare professionals by providing a novel cancer treatment option through the co-promotion activities. The companies will continue their commitment to the advancement in cancer therapy in the course of their business activities.